The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.

Q2 Medicine HIV Clinical Trials Pub Date : 2017-07-01 Epub Date: 2017-07-18 DOI:10.1080/15284336.2017.1349028
Mark J Siedner, Mwebesa B Bwana, Mahomed-Yunus S Moosa, Michelle Paul, Selvan Pillay, Suzanne McCluskey, Isaac Aturinda, Kevin Ard, Winnie Muyindike, Pravikrishnen Moodley, Jaysingh Brijkumar, Tamlyn Rautenberg, Gavin George, Brent Johnson, Rajesh T Gandhi, Henry Sunpath, Vincent C Marconi
{"title":"The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.","authors":"Mark J Siedner,&nbsp;Mwebesa B Bwana,&nbsp;Mahomed-Yunus S Moosa,&nbsp;Michelle Paul,&nbsp;Selvan Pillay,&nbsp;Suzanne McCluskey,&nbsp;Isaac Aturinda,&nbsp;Kevin Ard,&nbsp;Winnie Muyindike,&nbsp;Pravikrishnen Moodley,&nbsp;Jaysingh Brijkumar,&nbsp;Tamlyn Rautenberg,&nbsp;Gavin George,&nbsp;Brent Johnson,&nbsp;Rajesh T Gandhi,&nbsp;Henry Sunpath,&nbsp;Vincent C Marconi","doi":"10.1080/15284336.2017.1349028","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In sub-Saharan Africa, rates of sustained HIV virologic suppression remain below international goals. HIV resistance testing, while common in resource-rich settings, has not gained traction due to concerns about cost and sustainability.</p><p><strong>Objective: </strong>We designed a randomized clinical trial to determine the feasibility, effectiveness, and cost-effectiveness of routine HIV resistance testing in sub-Saharan Africa.</p><p><strong>Approach: </strong>We describe challenges common to intervention studies in resource-limited settings, and strategies used to address them, including: (1) optimizing generalizability and cost-effectiveness estimates to promote transition from study results to policy; (2) minimizing bias due to patient attrition; and (3) addressing ethical issues related to enrollment of pregnant women.</p><p><strong>Methods: </strong>The study randomizes people in Uganda and South Africa with virologic failure on first-line therapy to standard of care virologic monitoring or immediate resistance testing. To strengthen external validity, study procedures are conducted within publicly supported laboratory and clinical facilities using local staff. To optimize cost estimates, we collect primary data on quality of life and medical resource utilization. To minimize losses from observation, we collect locally relevant contact information, including Whatsapp account details, for field-based tracking of missing participants. Finally, pregnant women are followed with an adapted protocol which includes an increased visit frequency to minimize risk to them and their fetuses.</p><p><strong>Conclusions: </strong>REVAMP is a pragammatic randomized clinical trial designed to test the effectiveness and cost-effectiveness of HIV resistance testing versus standard of care in sub-Saharan Africa. We anticipate the results will directly inform HIV policy in sub-Saharan Africa to optimize care for HIV-infected patients.</p>","PeriodicalId":13216,"journal":{"name":"HIV Clinical Trials","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/15284336.2017.1349028","citationCount":"18","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Clinical Trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15284336.2017.1349028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/7/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 18

Abstract

Background: In sub-Saharan Africa, rates of sustained HIV virologic suppression remain below international goals. HIV resistance testing, while common in resource-rich settings, has not gained traction due to concerns about cost and sustainability.

Objective: We designed a randomized clinical trial to determine the feasibility, effectiveness, and cost-effectiveness of routine HIV resistance testing in sub-Saharan Africa.

Approach: We describe challenges common to intervention studies in resource-limited settings, and strategies used to address them, including: (1) optimizing generalizability and cost-effectiveness estimates to promote transition from study results to policy; (2) minimizing bias due to patient attrition; and (3) addressing ethical issues related to enrollment of pregnant women.

Methods: The study randomizes people in Uganda and South Africa with virologic failure on first-line therapy to standard of care virologic monitoring or immediate resistance testing. To strengthen external validity, study procedures are conducted within publicly supported laboratory and clinical facilities using local staff. To optimize cost estimates, we collect primary data on quality of life and medical resource utilization. To minimize losses from observation, we collect locally relevant contact information, including Whatsapp account details, for field-based tracking of missing participants. Finally, pregnant women are followed with an adapted protocol which includes an increased visit frequency to minimize risk to them and their fetuses.

Conclusions: REVAMP is a pragammatic randomized clinical trial designed to test the effectiveness and cost-effectiveness of HIV resistance testing versus standard of care in sub-Saharan Africa. We anticipate the results will directly inform HIV policy in sub-Saharan Africa to optimize care for HIV-infected patients.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在撒哈拉以南非洲评估艾滋病毒耐药性检测的REVAMP试验:在资源有限的环境中优化有效性和成本效益估计的临床试验设计案例研究。
背景:在撒哈拉以南非洲,艾滋病毒病毒学持续抑制率仍低于国际目标。艾滋病毒耐药性检测虽然在资源丰富的环境中很常见,但由于对成本和可持续性的担忧,尚未获得关注。目的:我们设计了一项随机临床试验,以确定撒哈拉以南非洲地区常规艾滋病毒耐药性检测的可行性、有效性和成本效益。方法:我们描述了在资源有限的情况下干预研究的常见挑战,以及用于解决这些挑战的策略,包括:(1)优化概括性和成本效益估算,以促进从研究结果到政策的过渡;(2)尽量减少因患者流失造成的偏倚;(3)解决孕妇入组的伦理问题。方法:该研究将乌干达和南非一线治疗病毒学失败的患者随机分组到标准护理病毒学监测或立即耐药性检测中。为了加强外部有效性,研究程序在公共支持的实验室和临床设施中使用当地工作人员进行。为了优化成本估算,我们收集了有关生活质量和医疗资源利用的原始数据。为了尽量减少观察造成的损失,我们收集了当地相关的联系信息,包括Whatsapp账户详细信息,以便现场跟踪失踪的参与者。最后,对孕妇进行调整后的治疗方案,其中包括增加就诊频率,以尽量减少对孕妇及其胎儿的风险。结论:REVAMP是一项实用的随机临床试验,旨在测试艾滋病毒耐药性检测与撒哈拉以南非洲标准护理的有效性和成本效益。我们预计研究结果将直接为撒哈拉以南非洲的艾滋病毒政策提供信息,以优化对艾滋病毒感染患者的护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
HIV Clinical Trials
HIV Clinical Trials 医学-传染病学
CiteScore
1.76
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: HIV Clinical Trials is devoted exclusively to presenting information on the latest developments in HIV/AIDS clinical research. This journal enables readers to obtain the most up-to-date, innovative research from around the world.
期刊最新文献
Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. Participant characteristics and clinical trial decision-making factors in AIDS malignancy consortium treatment trials for HIV-infected persons with cancer (AMC #S006). Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry. Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1